OVID THERAPEUTICS INC (OVID)

Company Profile

Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The company went IPO on 2017-05-05. The firm is focused on developing medicines for patients and families living with epilepsies and seizure-related neurological disorders. The firm is developing OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. The Company’s genetic research programs include OV815 and OV825 and OV882. OV815 focuses on the mutations associated with KIF1A-associated neurological disorder (KAND). OV825 has advanced to candidate lead identification for the rare neurodevelopmental condition HNRNPH2. OV882 is a short hairpin RNA that the Company is evaluating as a potential disease-modifying gene therapy for Angelman syndrome. OV329 is an investigational, next-generation GABA-AT inhibitor that the Company is developing for the treatment of adult and pediatric epilepsy disorders.

Company Info

OVID THERAPEUTICS INC

441 Ninth Avenue, 14Th Floor

New York City NEW YORK 10036

P: 12127764381

CEO: Jeremy M. Levin

Employees: 39

Website: https://ovidrx.com/